Text

Patent Strategy in Pharmaceutical industry : Are Additional Patents Valuable?

---

This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.

---

Availability

No copy data

Detail Information

Series Title

-

Call Number

340 DON p

Publisher

: Nomos Verlagsgesellschaft., 2014

Collation

84 halaman

Language

English

ISBN/ISSN

9783845251288

Classification

340

Content Type

text

Media Type

computer

Carrier Type

online resource

Edition

-

Subject(s)

Law / Commercial

Specific Detail Info

-

Statement of Responsibility

Monica Donghi

Other Information

Cataloger

agus

Source

-

Validator

maya

Digital Object Identifier (DOI)

-

Journal Volume

-

Journal Issue

-

Subtitle

-

Parallel Title

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment